Recursion Pharmaceuticals, Inc. (RXRX) Stock Profile & Financial OverviewRecursion Pharmaceuticals, Inc.
RXRX Company Overview & Business Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Key Information
Current Trend for RXRX
An assessment of the current trend environment for RXRX, based on the latest closing price data and intended to describe the market context heading into the next trading session.
As of 2025-12-24, the current trend for RXRX is a Sideways Consolidation (Range-Bound Environment).
The weekly trend is in a consolidation regime, which automatically downgrades the daily signal to sideways conditions. This environment favors short-term mean-reversion rather than trend-following.
- The weekly context is non-trending (sideways), which typically caps the duration and magnitude of daily trend moves.
- Price is currently compressing tightly (optimal low-risk zone), sitting -0.23 ATR away from the adaptive KAMA baseline.
- The current market structure is holding within recent defined ranges.
Explore More Data
Adaptive Trend Model · Daily & Weekly (2025-12-24 ET)
This model uses an adaptive trend algorithm based on daily and weekly price data to identify whether a stock is in an uptrend, downtrend, or consolidation over a multi-week to multi-month horizon. Compared with traditional moving-average systems, it filters short-term noise more effectively, captures trend continuation more reliably, and provides a stronger basis for position sizing and risk-management decisions such as stop-loss and take-profit levels.
As of 2025-12-24, RXRX in a non-directional consolidation; Long-term trend is bullish.
Trend Strength: RXRX last closed at 4.40, trading 0.1 ATR below the adaptive KAMA baseline (4.43). Technical Classification: Non-Directional / Range-Bound.
Trend Score: Technical Score: 35/100. Classification: Sideways. Alignment: Indeterminate. Logic: Price action is range-bound or lacking sufficient slope for trend confirmation.
SuperTrend Risk: Risk indicators: No active structural constraints identified.
Risk Skew: Multi-timeframe risk skew is currently assessed as Non-Directional. Price is oscillating within a low-momentum range. Risk is two-sided, favoring mean-reversion strategies over trend-following.
Key Levels: Key technical references: Spot 4.40, KAMA 4.43.